The Partnership for Safe Medicines (PSM) has documented 50 actions by state boards of pharmacy against compounders operating unsafely since 2025, alongside 160 letters issued by the FDA to pharmacies and peptide vendors. The figures, reported by NBC Bay Area on September 3, 2026, represent the most comprehensive public accounting to date of the enforcement wave tied to the surge in unapproved GLP-1 drugs.
The actions tracked by PSM include license probation and revocation, according to the NBC Bay Area investigation, which examined the broader impact of unapproved GLP-1 products on poison control centers and safe medicine advocates. The 160 FDA letters were directed at telehealth companies and compounders.
PSM’s data is a tracked tally of reported enforcement actions — not a complete government enforcement database. But the numbers indicate that state and federal regulators are acting in parallel, creating what observers describe as a two-front compliance challenge for compounding pharmacies and telehealth platforms.
What happened
PSM, a coalition that monitors counterfeit and unsafe medicines, began tracking enforcement actions against compounders as unapproved GLP-1 drugs proliferated. Since 2025, the organization has recorded:
- 50 actions by state boards of pharmacy, including license probation and revocation
- 160 FDA letters to pharmacies and peptide vendors, including telehealth companies
NBC Bay Area reported the figures as part of an investigation into the unapproved GLP-1 drug market. The report also considered the impact of the unapproved GLP-1 market on safe medicine advocates, alongside its effects on poison control centers.
Why it matters
For compounding pharmacy operators, telehealth platforms, and peptide clinics, the data indicates that enforcement is not limited to a single agency or jurisdiction. State boards and the FDA are acting simultaneously, meaning operators face scrutiny at both levels.
For investors and founders in the peptide and telehealth space, the breadth of enforcement signals that the regulatory surface area extends well beyond any individual warning letter or board action. The PSM tally also provides a benchmark for understanding the scale of the regulatory response tracked so far to the unapproved GLP-1 surge.
The affected groups identified in the reporting include 503A compounding pharmacies, telehealth peptide platforms, state pharmacy boards, peptide consumers, and poison control centers — underscoring that the enforcement wave touches clinical, commercial, and public health channels.
What to watch next
- Whether state board actions and FDA letters continue to accumulate through the remainder of 2026
- How poison control centers report GLP-1-related incidents going forward
- Whether additional telehealth platforms or compounding pharmacies face public enforcement
- Whether PSM or other organizations release more granular data on specific actions and outcomes
Sources
Industry information only. Not medical or legal advice.
